Pyxis Oncology, Inc.
PYXS
$1.04
-$0.005-0.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.15M | 16.15M | 16.15M | 16.15M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.15M | 16.15M | 16.15M | 16.15M | -- |
| Cost of Revenue | 475.00K | 475.00K | 475.00K | 475.00K | -- |
| Gross Profit | 15.67M | 15.67M | 15.67M | 15.67M | -- |
| SG&A Expenses | 22.49M | 23.71M | 28.47M | 29.27M | 30.83M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.72M | 80.52M | 82.22M | 80.46M | 80.42M |
| Operating Income | -65.57M | -64.37M | -66.08M | -64.31M | -80.42M |
| Income Before Tax | -79.50M | -57.36M | -59.20M | -57.80M | -73.79M |
| Income Tax Expenses | -2.16M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -77.33 | -57.36 | -59.20 | -57.80 | -73.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -77.33M | -57.36M | -59.20M | -57.80M | -73.79M |
| EBIT | -65.57M | -64.37M | -66.08M | -64.31M | -80.42M |
| EBITDA | -62.59M | -61.25M | -63.16M | -61.46M | -78.49M |
| EPS Basic | -1.28 | -1.05 | -1.26 | -1.39 | -1.87 |
| Normalized Basic EPS | -0.61 | -0.66 | -0.79 | -0.87 | -1.17 |
| EPS Diluted | -1.28 | -1.05 | -1.26 | -1.39 | -1.87 |
| Normalized Diluted EPS | -0.61 | -0.66 | -0.79 | -0.87 | -1.17 |
| Average Basic Shares Outstanding | 233.75M | 216.98M | 197.60M | 175.49M | 159.55M |
| Average Diluted Shares Outstanding | 233.75M | 216.98M | 197.60M | 175.49M | 159.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |